S. Bell

发表

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

G. Morgan, W. Gregory, M. Drayson, 2012, Haematologica.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Faith, G. Morgan, P. Sonneveld, 2008, Blood.

transplantation therapy for patients with multiple myeloma unsuitable for autologous Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial

G. Morgan, W. Gregory, M. Drayson, 2014 .

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

G. Morgan, W. Gregory, M. Drayson, 2013, Clinical Cancer Research.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

G. Morgan, W. Gregory, M. Drayson, 2012, Blood.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

G. Morgan, W. Gregory, M. Drayson, 2011, Blood.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

G. Morgan, W. Gregory, M. Drayson, 2010, The Lancet.

SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection

R. Booton, W. Gregory, C. Faivre-Finn, 2020, European Respiratory Journal.

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

G. Morgan, W. Gregory, M. Drayson, 2014, British journal of haematology.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

G. Morgan, W. Gregory, W. Tapper, 2011, Leukemia.

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

G. Morgan, W. Gregory, M. Drayson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma

G. Cook, J. Snowden, J. Cavenagh, 2014, International journal of laboratory hematology.

Are we over-treating with checkpoint inhibitors?

P. Corrie, S. Danson, H. Marshall, 2019, British Journal of Cancer.

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

G. Morgan, W. Gregory, M. Drayson, 2018, British Journal of Haematology.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

G. Morgan, W. Gregory, M. Drayson, 2015, Blood.

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.

G. Morgan, W. Gregory, M. Drayson, 2007 .

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

G. Morgan, M. Drayson, F. Davies, 2003, The New England journal of medicine.

The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

R. Plummer, F. Gallagher, J. Bestall, 2021, BMC cancer.

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

G. Morgan, W. Gregory, M. Drayson, 2011, The Lancet. Oncology.

Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial

J. Snowden, J. Cavenagh, G. Cook, 2013, British journal of haematology.

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

G. Morgan, W. Gregory, M. Drayson, 2016, Haematologica.

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

G. Morgan, W. Gregory, M. Drayson, 2012, Blood.

Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.

G. Morgan, W. Gregory, W. Tapper, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

G. Morgan, W. Gregory, M. Drayson, 2011 .

Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT

Napp, D. Altman, C. Sturgeon, 2018, Programme Grants for Applied Research.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

G. Morgan, W. Gregory, M. Drayson, 2015, Blood.